This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Meridian Bioscience Reports Record Fourth Quarter And Full-Year Operating Results, Declares Regular Cash Dividend, Announces Increased Regular Cash Dividend Rate For Fiscal 2014, And Reaffirms Fiscal 2014 Guidance

Meridian Bioscience, Inc. (NASDAQ: VIVO):


Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
  • reported record fourth quarter and full-year fiscal 2013 net sales of $49.0 million and $188.7 million, respectively, increases of 13% and 9%, respectively, from the same periods of the prior fiscal year;
  • reported record fourth quarter and full-year fiscal 2013 operating income of $13.3 million and $57.3 million, respectively, increases of 10% and 16%, respectively, from the same periods of the prior fiscal year;
  • reported record fourth quarter fiscal 2013 net earnings of $9.2 million, or $0.22 per diluted share, increases of 7% and 5%, respectively, compared to the fiscal 2012 fourth quarter;
  • reported full-year fiscal 2013 net earnings of $38.0 million, or $0.91 per diluted share, increases of 14% compared to fiscal 2012. When compared to the fiscal 2012 net earnings on a non-GAAP basis, the full-year fiscal 2013 net earnings and net earnings per diluted share each increased 12% and 11%, respectively. This non-GAAP financial measure excludes the effect of fiscal 2012 costs associated with the consolidation of its Saco, Maine operations into its Tennessee facility (see non-GAAP financial measure reconciliations);
  • declared the regular quarterly cash dividend of $0.19 per share for the fourth quarter of fiscal 2013, (indicated annual rate of $0.76 per share), the same as the regular quarterly rate of fiscal 2012;
  • announced a 5% increase in the annual indicated cash dividend for fiscal 2014 from $0.76 to $0.80 per share; and
  • reaffirmed its fiscal 2014 guidance of per share diluted earnings between $0.98 and $1.03 on net sales of $203 million to $208 million.


In Thousands, Except per Share Data
        Three Months Ended     Twelve Months Ended
September 30, September 30,
2013   2012   % Change 2013   2012   % Change
Net Sales $ 48,962 $ 43,483 13 % $ 188,686 $ 172,712 9 %
Operating Income 13,271 12,052 10 % 57,314 49,296 16 %
Net Earnings 9,150 8,573 7 % 38,032 33,371 14 %
Diluted Earnings per Share $ 0.22 $ 0.21 5 % $ 0.91 $ 0.80 14 %
Diluted Earnings per Share
excluding effect of plant
consolidation costs (2012)
(see non-GAAP financial measure
reconciliations) $ 0.22 $ 0.21 5 % $ 0.91 $ 0.82 11 %
September 30,
2013 2012
Cash and Equivalents $ 44,282 $ 31,593
Working Capital 92,385 78,128
Shareholders’ Equity 155,045 142,748
Total Assets 176,748 161,381


John A. Kraeutler, Chief Executive Officer, said, “Our financial and strategic achievements in fiscal 2013 were very satisfying and included key contributions from all operating units. Revenues of $189 million represented a 9% increase over fiscal 2012 with net earnings expanding by 14%, which translated to EPS of $0.91. In the Diagnostics segment, sales of our illumigene® molecular product line grew by 45% and contributed more than $33 million, nearly 25% of segment revenues. Of this, illumigene tests for C. difficile contributed approximately 80% of the total, with Group B strep accounting for 12% and Group A strep 5%. In the immunoassay category, double-digit growth continued in rapid tests for foodborne related diseases, up 15%, and in H. pylori tests for stomach ulcers, up 11%. These two product categories now represent more than $50 million of annual revenues. The 4% growth in our Life Science business was comprised of a strong 10% increase in Bioline revenues, driven largely by new products including SensiFast and MyTaq™, offset by flat sales from the core unit.

“We continued to drive operating efficiency during the year and, despite the additional Medical Device Tax burden, overall gross profit margins were strong at 64%. Operating income increased by almost 200 basis points to 30% and, importantly, the Life Science business improved its operating income by 12% (excluding 2012 Plant consolidation costs), reflecting a clear focus on driving growth while maximizing returns.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs